Location History:
- Erlangen, DE (2006)
- Ulm, DE (2010 - 2012)
- Neu-Ulm, DE (2014 - 2015)
- Hannover, DE (2019)
Company Filing History:
3 out of 6 
1 out of 2 
1 out of 8 Years Active: 2006-2019
Title: Jan Münch: Innovator in Peptide Research
Introduction
Jan Münch is a prominent inventor based in Ulm, Germany. He has made significant contributions to the field of peptide research, particularly in the development of peptides with antagonistic activities against the CXCR4 receptor. His innovative work has led to the filing of several patents, showcasing his expertise and dedication to advancing medical science.
Latest Patents
Jan Münch holds 7 patents that reflect his groundbreaking research. His latest patents include a peptide effective in blocking the CXC-chemokine receptor 4 (CXCR4) mediated HIV-1 NL4-3 (X4-tropic) infection, demonstrating an IC value of less than 50 µM. Another notable patent involves a CXC chemokine receptor 4 (CXCR4) antagonistic polypeptide, which encompasses a specific amino acid sequence and its biologically active fragments, variants, and derivatives. These innovations are crucial in the ongoing fight against HIV and related diseases.
Career Highlights
Throughout his career, Jan Münch has worked with notable companies such as Ipf Pharmaceuticals GmbH and Pharis Biotech GmbH. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to significant advancements in peptide technology.
Collaborations
Jan Münch has collaborated with esteemed colleagues, including Frank Kirchhoff and Wolf-Georg Forssmann. These partnerships have enriched his research and expanded the impact of his innovations in the scientific community.
Conclusion
Jan Münch is a distinguished inventor whose work in peptide research has led to important advancements in medical science. His patents and collaborations reflect his commitment to innovation and the betterment of healthcare.